Antibody-Drug Conjugate Market - Industry Dynamics, Market Size, and Opportunity Forecast to 2035

Antibody-Drug Conjugate Market: By Product (Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, Blenrep, Others); Target Antigen (HER2, CD30, TROP-2, CD22, Nectin-4, BCMA, Others); Payload / Technology (Auristatins (MMAE / MMAF), Maytansinoids (DM1 / DM4), Calicheamicins, Topoisomerase Inhibitors (DXd), Others); Linker Type (Cleavable, Non-Cleavable); Indication (Breast Cancer, Hematologic / Blood Cancers, Lung Cancer, Bladder / Urothelial Cancer, Ovarian Cancer, Others); End User (Hospitals, Specialty & Cancer Centers, Others)— Market Size, Industry Dynamics, Opportunity Analysis And Forecast For 2026–2035

Global antibody-drug conjugate (ADC) market size was valued at USD 14.23 billion in 2025 and is projected to hit the market valuation of USD 45.39 billion by 2035 at a CAGR of 12.30% during the forecast period 2026–2035. Read More

We Are Trusted By These Great Companies!

• Last Updated: 12-Jun-2026  |  Format:  |  Report ID: AA06261828